A randomized, placebo-controlled trial of BPS804 on safety and tolerability in patients with late-stage chronic kidney disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003348-63

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to assess the safety and tolerability following administration of a single dose of BPS804 in patients with CKD-5D.


Critère d'inclusion

  • Patients with chronic kidney disease stage 5D (CKD-5D) and evidence of mineral and bone disorder as judged by low serum intact PTH levels according to KDIGO guidelines

Liens